Anticonvulsant osteomalacia.
Drug-induced osteomalacia appears to be a relatively common disorder in patients receiving long-term anticonvulsant drug therapy. The severity of clinical manifestations in any given individual appears to be a function of the combined effects of a variety of factors including drug type and total drug dose, dietary vitamin D intake, sunlight exposure, and physical activity level. Aided by the recent development of sensitive techniques such as the serum 25-hydroxyvitamin D assay and the photon absorption methods for bone mass determination, one can now detect abnormalities in vitamin D and bone metabolism with much greater precision. As a consequence, the incidence of  disordered mineral metabolism in patients receiving long-term anti-convulsant therapy can be determined with greater precision and therapeutic regimens instituted to prevent the associated morbidity.
D000293:Adolescent; D000927:Anticonvulsants / Q000009:adverse effects*; D001842:Bone and Bones / Q000378:metabolism; D006801:Humans; D008297:Male; D008617:Mephenytoin / Q000009:adverse effects / Q000627:therapeutic use; D008903:Minerals; D010018:Osteomalacia / Q000139:chemically induced*; D010634:Phenobarbital / Q000009:adverse effects / Q000627:therapeutic use; D010672:Phenytoin / Q000009:adverse effects / Q000627:therapeutic use; D012640:Seizures / Q000097:blood / Q000188:drug therapy; D014807:Vitamin D / Q000097:blood
D000927:Anticonvulsants; D008903:Minerals; D014807:Vitamin D; D010672:Phenytoin; D008617:Mephenytoin; D010634:Phenobarbital